Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for painful hand and foot pustules: phase 3 trial launches

NCT ID NCT07219420

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 6 times

Summary

This phase 3 trial tests whether the drug bimekizumab can clear or nearly clear the pustules and skin lesions of palmoplantar pustulosis (PPP) on the hands and feet. About 320 adults with moderate to severe PPP will receive either bimekizumab or a placebo for 16 weeks, with an option to continue on the drug afterward. The main goal is to see how many achieve clear or almost clear skin at week 16.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bimekizumab (BIMZELX)
What this could lead to
If it works, this could provide a new treatment option for people with painful pustules on hands and feet.
What could go wrong
This is a late-stage trial, but results may not apply to all patients. Side effects are possible, and the drug may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age inclusive, at the time of signing the informed consent form (ICF) * Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit * Have PPPASI ≥12 at the Screening Visit and Baseline Visit * Have PPP-IGA ≥3 at the Screening Visit and Baseline Visit * Have pustules on the palms of the hands and/or soles of the feet at the Screening Visit and Baseline Visit, defined as pustule severity ≥2 and having more than 5 active pustules * Participant must be a candidate for systemic therapy or phototherapy Exclusion Criteria: * Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score * Has the following: palmoplantar PSO (plaque PSO on palms/soles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema. * Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor \[TNF\] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis) * Has cutaneous lesions that may interfere with the evaluation of the affected area and/or evaluation of the severity of PPP * Is taking or has taken prohibited or restricted medications without meeting the mandatory discontinuation or stability period relative to the Baseline Visit * Is taking or has ever taken an interleukin (IL)-17A/IL-17F inhibitor, including bimekizumab, or has participated in a bimekizumab investigational study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmoplantar pustulosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis periodontitis, aggressive 1 psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Palmoplantar pustulosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    91 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ppp001 20022

    RECRUITING

    Hangzhou, China

  • Ppp001 20104

    RECRUITING

    Seoul, South Korea

  • Ppp001 20136

    RECRUITING

    Tianjin, China

  • Ppp001 20137

    RECRUITING

    Chengdu, China

  • Ppp001 20184

    RECRUITING

    Shenzhen, China

  • Ppp001 20193

    RECRUITING

    Hangzhou, China

  • Ppp001 20208

    RECRUITING

    Seongnam-si, South Korea

  • Ppp001 20211

    RECRUITING

    Bucheon-si, South Korea

  • Ppp001 20214

    RECRUITING

    Busan, South Korea

  • Ppp001 20215

    RECRUITING

    Gwangju, South Korea

  • Ppp001 20216

    RECRUITING

    Seoul, South Korea

  • Ppp001 20220

    RECRUITING

    Seoul, South Korea

  • Ppp001 20311

    RECRUITING

    Guangzhou, China

  • Ppp001 20313

    RECRUITING

    Guangzhou, China

  • Ppp001 20344

    RECRUITING

    Jinan, China

  • Ppp001 20345

    RECRUITING

    Shanghai, China

  • Ppp001 20350

    RECRUITING

    Chongqing, China

  • Ppp001 20351

    RECRUITING

    Seoul, South Korea

  • Ppp001 20352

    RECRUITING

    Chengdu, China

  • Ppp001 20353

    RECRUITING

    Yinchuan, China

  • Ppp001 20354

    RECRUITING

    Seoul, South Korea

  • Ppp001 20355

    RECRUITING

    Jinan, China

  • Ppp001 20356

    RECRUITING

    Xi'an, China

  • Ppp001 20357

    RECRUITING

    Beijing, China

  • Ppp001 20359

    RECRUITING

    Seoul, South Korea

  • Ppp001 20366

    RECRUITING

    Anyang-si, South Korea

  • Ppp001 20367

    RECRUITING

    Jeonju, South Korea

  • Ppp001 40067

    RECRUITING

    Lyon, France

  • Ppp001 40108

    RECRUITING

    Salford, United Kingdom

  • Ppp001 40113

    RECRUITING

    London, United Kingdom

  • Ppp001 40177

    RECRUITING

    Münster, Germany

  • Ppp001 40203

    RECRUITING

    Budapest, Hungary

  • Ppp001 40230

    RECRUITING

    Valencia, Spain

  • Ppp001 40249

    RECRUITING

    Kiel, Germany

  • Ppp001 40266

    RECRUITING

    Badalona, Spain

  • Ppp001 40297

    RECRUITING

    Manises, Spain

  • Ppp001 40334

    RECRUITING

    Wroclaw, Poland

  • Ppp001 40356

    RECRUITING

    Dresden, Germany

  • Ppp001 40366

    RECRUITING

    Rostock, Germany

  • Ppp001 40396

    RECRUITING

    Rzeszów, Poland

  • Ppp001 40515

    RECRUITING

    Berlin, Germany

  • Ppp001 40567

    RECRUITING

    Roma, Italy

  • Ppp001 40604

    RECRUITING

    Warsaw, Poland

  • Ppp001 40625

    RECRUITING

    Lodz, Poland

  • Ppp001 40626

    RECRUITING

    Bialystok, Poland

  • Ppp001 40637

    RECRUITING

    Gdansk, Poland

  • Ppp001 40740

    RECRUITING

    Bad Bentheim, Germany

  • Ppp001 40743

    RECRUITING

    Szczecin, Poland

  • Ppp001 40747

    RECRUITING

    Mainz, Germany

  • Ppp001 40748

    RECRUITING

    Plzen-bory, Czechia

  • Ppp001 40750

    RECRUITING

    Alicante, Spain

  • Ppp001 40757

    RECRUITING

    Poznan, Poland

  • Ppp001 40788

    RECRUITING

    Torun, Poland

  • Ppp001 40816

    RECRUITING

    Brescia, Italy

  • Ppp001 40830

    RECRUITING

    Rozzano, Italy

  • Ppp001 40862

    RECRUITING

    Wroclaw, Poland

  • Ppp001 40866

    RECRUITING

    Göttingen, Germany

  • Ppp001 40868

    RECRUITING

    Valencia, Spain

  • Ppp001 40874

    RECRUITING

    Nice, France

  • Ppp001 40875

    RECRUITING

    Ahaus, Germany

  • Ppp001 40876

    RECRUITING

    Warsaw, Poland

  • Ppp001 40878

    RECRUITING

    Katowice, Poland

  • Ppp001 40879

    RECRUITING

    Santiago de Compostela, Spain

  • Ppp001 40880

    RECRUITING

    London, United Kingdom

  • Ppp001 40881

    RECRUITING

    Ústí nad Labem, Czechia

  • Ppp001 40885

    RECRUITING

    Granada, Spain

  • Ppp001 40886

    RECRUITING

    Hellerup, Denmark

  • Ppp001 40887

    RECRUITING

    Toulon, France

  • Ppp001 40888

    RECRUITING

    Madrid, Spain

  • Ppp001 40889

    RECRUITING

    Málaga, Spain

  • Ppp001 40891

    RECRUITING

    Bielefeld, Germany

  • Ppp001 40892

    RECRUITING

    Lübeck, Germany

  • Ppp001 40893

    RECRUITING

    Bochum, Germany

  • Ppp001 40894

    RECRUITING

    Orosháza, Hungary

  • Ppp001 40895

    RECRUITING

    Debrecen, Hungary

  • Ppp001 40915

    RECRUITING

    Krakow, Poland

  • Ppp001 50176

    RECRUITING

    Fremont, California, 94538, United States

  • Ppp001 50202

    RECRUITING

    Fairborn, Ohio, 45324, United States

  • Ppp001 50233

    RECRUITING

    Barrie, Canada

  • Ppp001 50354

    RECRUITING

    Calgary, Canada

  • Ppp001 50733

    RECRUITING

    Mayfield Heights, Ohio, 44124, United States

  • Ppp001 50740

    RECRUITING

    Québec, Canada

  • Ppp001 50744

    RECRUITING

    Oklahoma City, Oklahoma, 73170, United States

  • Ppp001 50745

    RECRUITING

    Columbus, Ohio, 43213, United States

  • Ppp001 50746

    RECRUITING

    Miami, Florida, 33126, United States

  • Ppp001 50749

    RECRUITING

    Fredericton, Canada

  • Ppp001 50750

    RECRUITING

    Surrey, Canada

  • Ppp001 50752

    RECRUITING

    Red Deer, Canada

  • Ppp001 50754

    RECRUITING

    Birmingham, Alabama, 35205, United States

  • Ppp001 50757

    RECRUITING

    Auburn Hills, Michigan, 48326, United States

  • Ppp001 50765

    RECRUITING

    London, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.